¹³C₈-LY2835219

¹³C₈-LY2835219 is an isotopically labeled form of abemaciclib, a small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Abemaciclib is primarily used in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. The drug works by selectively inhibiting CDK4 and CDK6, which are key regulators of cell cycle progression from G1 to S phase. Inhibition leads to cell cycle arrest and reduced proliferation in cancer cells that rely on these kinases for growth[2][3][5]. The ^13C8-labeled version is typically used as an internal standard in pharmacokinetic studies or mass spectrometry assays rather than for direct therapeutic use.

Other names

abemaciclib (isotopically labeled)¹³C₈-abemaciclib